FDA-Initiated OTC Switches Could Be Based On Foreign Data – McClellan
This article was originally published in The Tan Sheet
Executive Summary
FDA may rely on a drug's foreign OTC marketing experience to determine whether an Rx product should be switched OTC in the U.S. without sponsor consent, Commissioner Mark McClellan, MD/PhD, said at a Manhattan Institute roundtable discussion for buyside analysts May 16